Cyclotron

RDX and HMX Market to Expand at CAGR of 3.8% Due to Rising Need For National Security in Various Countries, Says TMR

Retrieved on: 
Vendredi, novembre 5, 2021
NITRO, Mineral, Metal, Cyclotron, Urbanization, Chemring Group, CAGR, BRICS, HMX, Growth, Research, TNT, Coal mining, Industry, US, TMR, RDX, Explosive

The rising need for defending national borders and safety concerns is leading many countries to increase their military equipment and materials.

Key Points: 
  • The rising need for defending national borders and safety concerns is leading many countries to increase their military equipment and materials.
  • Transparency Market Research (TMR) has conducted an extensive research on various factors associated with the growth of the RDX and HMX market.
  • The analysts at TMR predict the global market for RDX and HMX to expand at a CAGR of 3.8% during the forecast period.
  • The spending on smart infrastructure due to global investments in the BRICS countries will also bolster the RDX and HMX market growth.

RDX and HMX Market to Expand at CAGR of 3.8% Due to Rising Need For National Security in Various Countries, Says TMR

Retrieved on: 
Vendredi, novembre 5, 2021
NITRO, Mineral, Metal, Cyclotron, Urbanization, Chemring Group, CAGR, BRICS, HMX, Growth, Research, TNT, Coal mining, Industry, US, TMR, RDX, Explosive

ALBANY, N.Y., Nov. 5, 2021 /PRNewswire/ -- RDX and HMX are common constituents of military explosives. They are used for various purposes, prominently in the military sector. In the military sector, RDX and HMX are used in melt-cast explosives, nuclear devices, booster charges, rocket fuels, plastic explosives, and others. In civilian aspects, they are used in demolition blocks, fireworks, and others. The growing demand for these constituents in various civilian and military applications is expected to offer extensive growth opportunities to the RDX and HMX market during the forecast period of 2021-2031.

Key Points: 
  • The rising need for defending national borders and safety concerns is leading many countries to increase their military equipment and materials.
  • Transparency Market Research (TMR) has conducted an extensive research on various factors associated with the growth of the RDX and HMX market.
  • The analysts at TMR predict the global market for RDX and HMX to expand at a CAGR of 3.8% during the forecast period.
  • The spending on smart infrastructure due to global investments in the BRICS countries will also bolster the RDX and HMX market growth.

Adler Institute for Advanced Imaging Introduces PET/CT Myocardial Perfusion Imaging With N-13 Ammonia To Area Physicians At Their Jenkintown, Pa Facility

Retrieved on: 
Jeudi, octobre 28, 2021
MRI, MD, CFR, Dementia, Technology, Diagnosis, Degenerative disease, Hospital, Cancer, Myocardial perfusion imaging, Cyclotron, Heart, Cardiac PET, CAD, Ammonia, PET, Medicine, Patient, MBF, Radiopharmaceutical, FDA, View, Adler, Physician, Microangiopathy, CT, COVID-19, Multimedia, Radiation exposure, Coronary artery disease, Half-life, Health, Miniaturization, MACE, Mathematics, Cardiology, PET/CT, N-13, Medical imaging

Adler Imaging is able to offer increased speed and access for cardiac PET/CT scanning on demand.

Key Points: 
  • Adler Imaging is able to offer increased speed and access for cardiac PET/CT scanning on demand.
  • Adler Imaging is one of only five sites nationwide to offer this latest advancement in outpatient cardiac imaging to patients and their doctors in their convenient outpatient office in Jenkintown.
  • For more information about Adler Imaging or PET/CT MYOCARDIAL PERFUSION IMAGING WITH N-13 AMMONIA, please call 215-935-0030or visit https://www.adlerimaging.com .
  • The Adler Institute for Advanced Imaging offers the latest innovation in high tech medical imaging, a combined positron emission tomography (PET) and computed tomography (CT) scanner.

Best Medical International & TeamBest Global Will Exhibit at ASTRO 2022 Meeting in San Antonio, Texas on October 23–26

Retrieved on: 
Mardi, octobre 26, 2021
Medical Supplies, Biotechnology, FDA, Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Research, Science, Clinical Trials, Proton, Carbon, Proton therapy, Cyclotron, Please, PET, Medical imaging, TBG, Partners Harvard Medical International, BMI, Information, News, Electronvolt, ASTRO, Particle therapy, Radiation therapy, Online shopping

Best Medical International (BMI) & TeamBest Global Companies (TBG) are announcing they will be exhibiting at the 2022 ASTRO Meeting that will be held in San Antonio, Texas, October 2326.

Key Points: 
  • Best Medical International (BMI) & TeamBest Global Companies (TBG) are announcing they will be exhibiting at the 2022 ASTRO Meeting that will be held in San Antonio, Texas, October 2326.
  • In addition, BMI will introduce Proton Therapy Cyclotrons up to 150 MeV and 400 MeV ion Rapid Cycling Medical Synchrotrons (iRCMS) for Proton-to-Carbon Heavy Ion High Precision Radiation Therapy.
  • Best Medical International & TeamBest Global Companies' booth floorplan layout is approximately 5000 sq.
  • ft. and will be positioned near the entrance of the ASTRO 2022 exhibit space in San Antonio, Texas.

Best Theratronics Ltd. Has Won Multiple International Tenders Worth 30 Million USD for New Cyclotron Systems & Upgrades

Retrieved on: 
Lundi, octobre 25, 2021
Radiology, Health, Medical Devices, Proton, Cyclotron, New Best Friends, Molecular imaging, TBG, News, BTL, Online shopping

Best Theratronics Ltd. (BTL), a member of TeamBest Global (TBG), has received multiple cyclotron orders Best 35 MeV High Current Proton Cyclotron Systems, Best 615 MeV High Current/Variable Energy Delivery Cyclotron System, and multiple technology upgrades to high energy cyclotrons by competing in International Tenders in Asia, Europe and the USA.

Key Points: 
  • Best Theratronics Ltd. (BTL), a member of TeamBest Global (TBG), has received multiple cyclotron orders Best 35 MeV High Current Proton Cyclotron Systems, Best 615 MeV High Current/Variable Energy Delivery Cyclotron System, and multiple technology upgrades to high energy cyclotrons by competing in International Tenders in Asia, Europe and the USA.
  • BTL manufactures a wide range of Proton Cyclotron Systems from 1150 MeV for research/radioisotope production/therapy and cyclotrons of various energies for Multi-Particle Alpha/Deuterons/Protons which are manufactured at Best Theratronics Ltd., in Ottawa, Ontario, Canada.
  • In addition, Best ABT Molecular Imaging (another member of the TBG Companies) located in Knoxville, Tennessee, USA, has manufactured and shipped five (5) Best BG-75 Cyclotrons this year alone, with plans to increase production substantially starting in early 2022.
  • This will allow the additional production of its other models, such as the NEW Best Model 200, as well as the Best Model 3d Low Energy Deuteron/Proton Cyclotron, along with other treatment delivery systems.

First Cyclotron Removed from Seneffe Production Facility by SCK CEN

Retrieved on: 
Lundi, octobre 18, 2021
General manager, Australian Securities Exchange, Industry, Publication, Environment, LinkedIn, ASX, SCK, Cancer, TGA, Employment, CEN, Degenerative disease, SCK CEN, Nuclear medicine, Cyclotron, MTR, Australian Radiation Protection and Nuclear Safety Agency, News, Patient, GLOBE, Economic development, Radioactive decay, Safety, TLX, Research, Partnership, AFCN, Saclay Nuclear Research Centre, Fine chemical

The cyclotron weighing approximately 22 tonnes was successfully removed by SCK CEN, a leader in nuclear safety and facility decommissioning.

Key Points: 
  • The cyclotron weighing approximately 22 tonnes was successfully removed by SCK CEN, a leader in nuclear safety and facility decommissioning.
  • Once the second cyclotron has been removed later this year, Telix will be able to formally commence the build-out of a new state-of-the-art facility for medical radioisotope production and drug product manufacturing.
  • The sooner Telix can start production, the sooner these important products can reach cancer patients," stated Michel Estas, decommissioning expert at SCK CEN.
  • Sbastien Linard de Guertechin, General Manager of the Seneffe Facility stated, Telix is delighted to be working with SCK CEN for the decommissioning.

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

Retrieved on: 
Dimanche, septembre 12, 2021

(Radius) for Telixs prostate cancer investigational imaging product Illuccix (Kit for the preparation of 68Ga-PSMA-11 injection) for the Italian market.

Key Points: 
  • (Radius) for Telixs prostate cancer investigational imaging product Illuccix (Kit for the preparation of 68Ga-PSMA-11 injection) for the Italian market.
  • This agreement builds on the support Radius has provided Telix in distributing 68Ga-PSMA-11 for magisterial use in Italy.
  • Radius CEO, Dr. Mauro Mei stated, This commercial partnership with Telix will enable us to open the door to state-of-the-art PSMA imaging for the 39,000 men diagnosed with prostate cancer each year in Italy.
  • Italy is an important market and we look forward to working with Radius to bring this highly anticipated imaging agent to Italian men, living with prostate cancer, once regulatory approval is received.

Eckert & Ziegler Extends Gallium-68 Generator Portfolio in the United States

Retrieved on: 
Vendredi, septembre 3, 2021
Oncology, Health, FDA, Medical Devices, Hospitals, Radiology, Biotechnology, Patient, Radionuclide, Neurology, PET, Cardiology, Nuclear medicine, Google Images, Cyclotron, Positron emission tomography, Wilms' tumor, General manager, Solution, Gesellschaft mit beschränkter Haftung, Radiopharmaceutical, Diagnosis, Investment, Molecular imaging, Research, Drug Master File, Medicine, DMF, Food, Prostate cancer, Cancer, Regulation of tobacco by the U.S. Food and Drug Administration, Medical imaging

Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File (DMF) to the U.S. Food and Drug Administration for GalliaPharm.

Key Points: 
  • Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File (DMF) to the U.S. Food and Drug Administration for GalliaPharm.
  • Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
  • With the development of generators with higher Ge-68 activity and the amendment of our DMF, we are responding to the increasing demand for Ga-68 based diagnostics in the United States, explained Dr Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment.
  • Eckert & Ziegler Radiopharma GmbH is a wholly owned subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG and part of Eckert & Zieglers Medical business segment.

New Radioisotope for Cancer Therapy - A new Collaboration to produce copper-67

Retrieved on: 
Mercredi, août 25, 2021
Cancer, Neuroblastoma, Government, University, Sterilization, Prostate, Research, Virtual College of Biotechnology, University of Saskatchewan, Wilms' tumor, Canadian Light Source, CLS, Cyclotron, Multimedia, Elective surgery, Politics of Saskatchewan, Graphite-moderated reactor, CIIC, Government of Canada, Radiation, Copper, Medical imaging

SASKATOON, SK, Aug. 25, 2021 /PRNewswire/ - Iotron Medical Inc. (Iotron) and Canadian Isotope Innovations Corp. (CIIC) are pleased to announce a collaboration to produce the radioisotope copper-67 (Cu-67) for new cancer therapies.

Key Points: 
  • SASKATOON, SK, Aug. 25, 2021 /PRNewswire/ - Iotron Medical Inc. (Iotron) and Canadian Isotope Innovations Corp. (CIIC) are pleased to announce a collaboration to produce the radioisotope copper-67 (Cu-67) for new cancer therapies.
  • This investment will increase the production capacity of the CIIC-operated facilities in Saskatoon, making Cu-67 more widely available to international cancer researchers.
  • Cu-67 has long been known for its excellent properties for personalized cancer therapy but has been extremely difficult to produce with sufficient quantity and purity using nuclear reactors or cyclotrons.
  • Lack of an adequate and reliable supply of this radioisotope has prevented medical researchers from exploring the potential of Cu-67 in new targeted cancer therapies.

DuChemBio Co., Ltd. & Life Molecular Imaging Announce Material Transfer And Clinical Supply Agreement for [18F]PI-2620 Tau PET Tracer

Retrieved on: 
Mardi, août 17, 2021
Transfer, Neurodegeneration, Tauopathy, Life Healthcare Group, PET/CT, Quality of life, Laboratory, Therapy, Amyloid, Acquisition, Diagnosis, Nuclear medicine, Research, Agreement, Disease, PET, Alzheimer's disease, DMD, DCB, Hospital, Cyclotron, Gesellschaft mit beschränkter Haftung, Molecular imaging, LMI, AD, IIT, Brain, Pharma, GMP, Drug development, Pharmaceutical industry, Medical imaging

SEOUL, South Korea and BERLIN, Aug. 17, 2021 /PRNewswire-PRWeb/ -- DuChemBio Co., Ltd. and Life Molecular Imaging (LMI) announced today the signing of a Material Transfer & Clinical Supply Agreement for LMI's next generation Tau PET Tracer PI-2620.

Key Points: 
  • SEOUL, South Korea and BERLIN, Aug. 17, 2021 /PRNewswire-PRWeb/ -- DuChemBio Co., Ltd. and Life Molecular Imaging (LMI) announced today the signing of a Material Transfer & Clinical Supply Agreement for LMI's next generation Tau PET Tracer PI-2620.
  • Supply of PI-2620 as a biomarker for local and DMD clinical trials research is expected to commence in the first half of 2022.
  • The introduction of a Tau tracer to South Korea through the supply of PI-2620 for clinical investigations is very exciting.
  • "LMI continues to expand the availability of innovative molecular imaging agents for clinical investigations," stated Ludger Dinkelborg, Ph.D., Managing Director at LMI.